Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Sep;3(3):164-73.
doi: 10.1007/s11764-009-0094-1. Epub 2009 Jun 26.

The impact of disease progression on perceived health status and quality of life of long-term cancer survivors

Melissa S Y Thong  1 , Floortje Mols, Jan-Willem W Coebergh, Jan A Roukema, Lonneke V van de Poll-Franse
Affiliations

The impact of disease progression on perceived health status and quality of life of long-term cancer survivors

Melissa S Y Thong et al. J Cancer Surviv. 2009 Sep.

Abstract

Introduction: The number of cancer survivors experiencing disease progression (DP) is increasing with the number of cancer survivors. However, little is known whether DP affects health-related quality of life (HRQL) of long-term cancer survivors. We aimed therefore to compare the health status (HS) and HRQL of DP and disease-free (DF) survivors up to 15 years after initial diagnosis.

Methods: 232 cancer survivors with DP identified through the Eindhoven Cancer Registry were matched with 232 DF survivors of similar demographic and clinical characteristics. Patients completed generic HS (SF-36) and cancer-specific HRQL (QOL-CS) questionnaires 5-15 years after diagnosis.

Results: Compared with DF survivors, DP survivors exhibited significantly lower scores on all SF-36 and QOL-CS (except spiritual well-being) dimensions. DF survivors had better scores than the normative population on all SF-36 dimensions. Among survivors with DP, those with short survival (<5 years) had significantly poorer HS scores on all dimensions except bodily pain compared with the normative population. Comparatively, the long survival (>or=5 years) DP group had better HRQL than the short DP group but poorer HRQL than the normative population. In multivariate analyses, DP and DF survival time were independently associated with aspects of HS and HRQL in cancer survivors.

Discussions/conclusions: DP cancer survivors have poorer long-term HS and HRQL compared with DF survivors. However, there is suggestion that HS and HRQL does improve over time following DP.

Implication for cancer survivors: Although DP survivors report poorer long-term HRQL compared with DF cancer survivors, results suggest that time can attenuate the distress of DP on HRQL. Psycho-educational programs could help to increase patients' sense of empowerment and personal control should DP occur.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Flow-chart of the data collection process.
FIGURE 2
FIGURE 2
Comparison of SF-36 scores according to disease status to the normative population standardized for age. An asterisk above a subgroup indicates a difference in the mean score between that subgroup and the normative population. PCS=Physical Component Summary score. MCS=Mental Component Summary score. **p < 0.001; *p < 0.05. ξ Indicates clinically significant difference in mean score between the subgroup and the norm population.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1016/j.ejca.2007.12.015', 'is_inner': False, 'url': 'https://doi.org/10.1016/j.ejca.2007.12.015'}, {'type': 'PubMed', 'value': '18280139', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/18280139/'}]}
    2. Karim-Kos HE, de Vries E, Soerjomataram I, Lemmens V, Siesling S, Coebergh JW. Recent trends of cancer in Europe: a combined approach of incidence, survival and mortality for 17 cancer sites since the 1990s. Eur J Cancer. 2008;44:1345–89. - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1016/S0959-8049(03)00489-1', 'is_inner': False, 'url': 'https://doi.org/10.1016/s0959-8049(03)00489-1'}, {'type': 'PubMed', 'value': '14522370', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/14522370/'}]}
    2. Ganz PA. Why and how to study the fate of cancer survivors: observations from the clinic and the research laboratory. Eur J Cancer. 2003;39:2136–41. - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1007/s10549-007-9556-1', 'is_inner': False, 'url': 'https://doi.org/10.1007/s10549-007-9556-1'}, {'type': 'PMC', 'value': 'PMC2217620', 'is_inner': False, 'url': 'https://pmc.ncbi.nlm.nih.gov/articles/PMC2217620/'}, {'type': 'PubMed', 'value': '17377838', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/17377838/'}]}
    2. Soerjomataram I, Louwman MW, Ribot JG, Roukema JA, Coebergh JW. An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Res Treat. 2008;107:309–30. - PMC - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1016/j.juro.2007.08.131', 'is_inner': False, 'url': 'https://doi.org/10.1016/j.juro.2007.08.131'}, {'type': 'PubMed', 'value': '17997449', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/17997449/'}]}
    2. Tran W, Serio AM, Raj GV, Dalbagni G, Vickers AJ, Bochner BH, et al. Longitudinal risk of upper tract recurrence following radical cystectomy for urothelial cancer and the potential implications for long-term surveillance. J Urol. 2008;179:96–100. - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1007/s10549-005-4016-2', 'is_inner': False, 'url': 'https://doi.org/10.1007/s10549-005-4016-2'}, {'type': 'PubMed', 'value': '16184464', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/16184464/'}]}
    2. Soerjomataram I, Louwman WJ, de Vries E, Lemmens VE, Klokman WJ, Coebergh JW. Primary malignancy after primary female breast cancer in the South of the Netherlands, 1972–2001. Breast Cancer Res Treat. 2005;93:91–5. - PubMed